ArticleDiscover oncology2026
RNF research trends and an RNF43-based prognostic model for colorectal cancer with immune microenvironment analysis.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The RING finger (RNF) protein family, the largest family of E3 ubiquitin ligases, plays a critical role in tumorigenesis and progression; however, a comprehensive macroscopic analysis of this field is still lacking. Colorectal cancer (CRC) is a highly prevalent malignancy worldwide, and its substantial heterogeneity urgently calls for more precise prognostic biomarkers. This study integrated bibliometric and bioinformatics approaches to systematically delineate the RNF research landscape, construct a CRC prognostic risk model based on the RNF43 interaction network, and explore its association with the tumor microenvironment (TME). Bibliometric analysis revealed that publications in the RNF field have increased rapidly (compound annual growth rate of 28.5%), with research hotspots shifting toward CRC and other diseases, and RNF43 emerging as a core frontier. Analysis of TCGA and GTEx data showed that RNF43 was significantly overexpressed in CRC. Through the STRING database, RNF43-interacting proteins were screened and intersected with CRC-related targets, identifying RNF43-mediated core CRC targets (RNF43, FZD1, FZD5, FZD8, LGR4, LGR5, RSPO1, RSPO2, RSPO3, RSPO4, and AKAP8L). Based on the TCGA-COAD+READ cohort (n = 541), these core targets were incorporated into LASSO regression analysis, resulting in a risk score model comprising LGR4, RSPO4, AKAP8L, and RNF43. In the training set (TCGA-COAD+READ), the high-risk group exhibited significantly shorter overall survival (OS), with AUCs of 0.61, 0.60, and 0.61 for 1-, 3-, and 5-year OS, respectively. The model was externally validated in the GSE39582 cohort (n = 579), although the AUC values remained modest. Multivariate Cox regression analysis demonstrated that the risk score, age, and tumor stage were independent prognostic factors for OS in CRC patients; a nomogram integrating these three factors showed acceptable calibration. TME analysis revealed that the high-risk group displayed a "pro-inflammatory phenotype under immunosuppression": increased infiltration of stromal components, increased CD8⁺ T cells but decreased CD4⁺ memory T cells, unexpectedly elevated M1 macrophages, and no significant difference in overall immune score. This complex imbalance pattern-characterized by increased effector cells, loss of memory cells, and pro-inflammatory polarization accompanied by potential functional suppression-suggests a possible mechanism of immune evasion. In conclusion, this study is the first to adopt a strategy combining "macro-level bibliometric insights" with "micro-level bioinformatics mining," systematically delineating the research trajectory of the RNF family and successfully constructing and validating a CRC prognostic risk model based on the RNF43 interaction network. This model may serve as an auxiliary stratification tool with potential prognostic value and may also reveal associations between the risk score and TME stromal activation and immune dysfunction, providing new insights for precise prognostic assessment and individualized treatment of CRC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.